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Abstract: Aim: Diabetes and periodontal disease are both chronic pathological conditions linked by
several underlying biological mechanisms, in which the inflammatory response plays a critical role,
and their association has been largely recognized. Recently, attention has been given to diabetes as
an important mediator of vascular endothelial growth factor (VEGF) overexpression in periodontal
tissues, by virtue of its ability to affect microvasculature. This review aims to summarize the findings
from studies that explored VEGF expression in diabetic patients with periodontitis, compared to
periodontally healthy subjects. Materials and Methods: A systematic literature review was performed
using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
A PubMed search of select medical subject heading (MeSH) terms was carried out to identify all
studies reporting findings about VEGF expression in periodontal tissues of diabetic patients up to
May 2018. The inclusion criteria were studies on VEGF expression in periodontally diseased tissues
of diabetic patients compared with nondiabetic subjects, with any method of analysis, and published
in the English language. Results: Eight articles met the inclusion criteria. Immunohistochemistry was
used in six of the studies, reverse transcriptase polymerase chain reaction (real-time RT-PCR) aiming
to quantify mRNA VEGF expression was used in one study, and ELISA analysis was used for one
study. Compared with nondiabetic patients, a higher VEGF expression in gingival tissue and gingival
crevicular fluid (GCF) samples in diabetic patients with periodontitis was reported. Conclusions:
Overall, novel evidence for the VEGF expression within the periodontal tissue of diabetic patients
paves the way for further studies on the role of this protein in neovascularization physiology and
pathophysiology in microvasculature of the periodontium.
Keywords: vascular endothelial growth factor; periodontitis; type II diabetes; type I diabetes;
periodontal disease
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1. Introduction
Diabetes and periodontal disease are both chronic pathological conditions linked by several
underlying biological mechanisms, in which the inflammatory response plays a critical role, and their
association has been largely recognized [1,2]. Periodontitis is an inflammatory disease affecting
supporting tissues of teeth [3,4]. Its chronicization is a key determinant of clinical manifestations and
underlying microvasculature alterations leading to irreversible damage [5]. It has been demonstrated
that diabetic patients are more prone to developing periodontitis, and, conversely [6,7], uncontrolled
diabetes is associated with higher risk for periodontitis onset and progression. Recently, in addition to
the established relationship between periodontitis and diabetes, attention has been given to diabetes as
an important mediator of vascular endothelial growth factor (VEGF) overexpression in periodontal
tissues, by virtue of its ability to induce vasoreactivity in many organs [8–11]. Vascular endothelial
growth factor (VEGF), a highly conserved heparin-binding homodimeric [12,13], disulfide-bound
glycoprotein of 45kDa, is a key mediator of angiogenesis, a complex process which leads to the new
growth of blood vessels from preexisting differentiated endothelial cells in the vascular network [14].
VEGF is a multifunctional growth factor implicated in embryonic development, and it is a powerful
angiogenic agent in physiological and pathological neovascularization [13–16]. The vascular endothelial
growth factor (VEGF) belongs to the endothelial growth factor family (VEGFs), currently consisting of
seven known members with a regulatory role in different vascular systems: VEGF-A, VEGF-B, VEGF-C,
VEGF-D, VEGF-E, VEGF-F, and PIGF [17]. VEGF exerts its biological effects through interaction with
specific (VEGF-R) receptors, which belong to the receptor tyrosine kinase (RTK) subfamily [3,5]; the
fms-like tyrosine kinase Flt-1 (VEGFR-1/Flt-1), the fetal liver kinase (VEGFR-2/KDR/Flk-1), and Flk-4
(VEGFR-3), causing proliferation of blood vessels (VEGF-A, VEGF-B, VEGF-C and VEGF-E) and
lymphangiogenesis (VEGF-C and VEGF-D) [14–16]. The vascular endothelial growth factor receptors
are one of the most important signaling pathways that regulate angiogenesis [17–20]. VEGFR-1 and
VEGFR-2 are primarily implicated in this process, and there is a growing body of evidence suggesting
that VEGFR-1 is involved in both physiological and pathological neovascularization [21–25]. The first
evidence for the role of VEGFR-1 during angiogenesis came from the finding that abnormal blood vessel
growth caused early embryogenic lethality when VEGFR-1 was targeted and deleted [2]. The negative
role of VEGFR-1 in angiogenesis has been demonstrated by animal studies, observing an increase
of endothelial cell progenitors and resulting in vascular disorganization as a consequence of loss of
VEGFR-1/flt-1 [26,27]. However, more recent in vitro evidence suggests that selective activation of
VEGFR-1 ligand is not linked to the proliferation of endothelial cells [28]. While the precise role of
VEGFR-1 in angiogenesis remains to be determined, the role of VEGFR-2 in neovascularization is
well recognized [28–30]. Upon binding, VEGFR-2 homo- or heterodimerizes with monomer receptors,
triggering autophosphorylation of its tyrosine residues with receptors that activate broad signaling
cascades, leading to different biological responses involving the activation of receptor tyrosine kinase
(RTKs) [30–32]. The binding of VEGF to its receptor promotes the activation of relay proteins that
transmit a signal into the nucleus of the endothelial cell. Subsequently, the nuclear signal induces
a group of genes to release molecules needed for new endothelial cell growth [33,34]. Among the
biological actions of VEGF, a role for this molecule in the direct control function of periodontal damage
in diabetic patients has been recently suggested [35–37]. Several lines of evidence confirm that VEGF is
a positive regulator of angiogenesis in physiological and pathological conditions [35,38], stimulating
extracellular matrix degradation, proliferation and migration of endothelial cells, and regulating
vascular permeability [39–43]. Several factors have been demonstrated as inductors of mRNA VEGF
transcription, including PDGF, EGF, TNF-α, TGF-β, and IL-1. Importantly, it has been found that VEGF
levels are also regulated via the hypoxia exposure; the tissue tension oxygen induces the expression
of VEGF irreversibly, through increased transcription and mRNA stabilization [44]. Pathological
angiogenesis is correlated with diabetic microvasculopathy in many organs, playing a critical role
in diabetic retinopathy [45,46], nephropathy [31,35], neuropathy [47], impaired collateral vessel
formation, and other systemic conditions. Several factors related to diabetes lead to angiogenic
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stimulation, and, primarily, the vascular endothelial growth factor (VEGF) signaling pathway is
involved [48,49]. Specifically, it has been demonstrated that diabetes causes defective VEGF signaling
leading to impairment of tyrosine kinase receptors Flk-1 activation, the receptor implicated in different
angiogenesis processes and in transmitting VEGF signaling [35]. This reduced activity results in
increased serum VEGF levels, causing pathologic angiogenesis [15]. Sasso et al. [50] have shown that
the reduction of Flt-1 and Flk-1 receptors influenced the VEGF expression in the myocardium of diabetic
patients, leading to a greater expression when compared to healthy subjects. Waltenberger et al. [35]
demonstrated that Flk-1 activation was abnormal in diabetic conditions. Furthermore, there other
several factors involved in abnormal angiogenesis in diabetes, including: (a) a chronic inflammatory
status with consequent secretions of pro-inflammatory molecules, characterizing diabetes mellitus,
which increases VEGF transcription hypoxia-inducible factor-1α (HIF-1α) [51–57]; (b) the hypoxic
condition, resulting in the upregulation of hypoxia inducible factors, which triggers cells to upregulate
VEGF and other pro-angiogenic agents [58]; (c) the presence of oxidative stress, which has been shown
to characterize diabetes, and is responsible for the secretion of proinflammatory cytokines such as
TNF-α, transforming growth factors alpha (TGF-α) and beta (TGF-β), and interleukins 6 (IL-6) and
8 (IL-8); and (d) hyperglycemia and advanced glycation end products (AGEs), which contribute to
impaired angiogenic potential [59–64] in vitro and other excess tissue factors.
2. Materials and Methods
A systematic literature review was performed using the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines. A PubMed search of select medical subject
heading (MeSH) terms to identify all studies that reported VEGF-expression in diabetic patients
with periodontitis findings to May 2019 was performed: “vascular endothelial growth factors “
OR “vascular” AND “endothelial” AND “growth” AND “factors” OR “vascular endothelial growth
factors” OR “vascular” AND “endothelial” AND “growth” AND “factors” OR “vascular endothelial
growth factors” AND “diabetes mellitus” OR “diabetes” AND “mellitus” OR “diabetes mellitus” OR
“diabetes” OR “diabetes insipidus” OR “diabetes” AND “insipidus” OR “diabetes insipidus” AND
“periodontitis” OR “periodontitis”. To be eligible, every study had to include the assessment of the
expression of vascular endothelial growth factor (VEGF) in diabetic patients with periodontal disease
and provide a healthy comparison, including non-diabetic patients with or without periodontal disease.
The following outcomes were extracted for each study, where available: type of analysis, number of
patients, setting, and analysis method, as shown in Tables 1 and 2.
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Table 1. Data extraction table.
STUDY Fusun Unlu (2003) Pelin Guneri (2004) Elif Eser Sakallioglu (2007) Simone Domenico Aspriello (2009)
PURPOSE
Determine the association
between VEGF expression in
healthy and periodontally
diseased tissues of healthy and
diabetic patients
Compare VEGF expression in
healthy and periodontally
diseased tissues with gingival
crevice fluid (GCF) of healthy
persons and diabetic patients
Demonstrate that DM may have
an inductive effect on the VEGF
levels of periodontium during
periodontal disease
Investigate VEGF expression and microvessel density
(MVD) in patients with periodontitis with and
without DM
SETTING
Department of Oral Diagnosis
and Radiology Department of
Ege University School of
Dentistry, TURKEY
Department of Oral Diagnosis
and Radiology Department of
Ege University School of
Dentistry, TURKEY
Department of Periodontology,
Faculty of Dentistry, Kurupelit,
TURKEY
Division of Periodontology, Department of Clinical and
Dental Sciences, Polytechnic
University of Marche, Torrette, Ancona, ITALY
SUBJECTS
n = 20
12 male, 8 females
Mean age = 52.6 years
n = 20
12 male, 8 females
Mean age = 52.6 years
n = 31 male
Mean age = 50.58 ± 1.54 years
n = 66
Age range, 47 to 71 years
INCLUSION CRITERIA
Previously diagnosed of type 2
DM, no smokers, patients with a
diagnosis of periodontitis
Previously diagnosed of type 2
DM, no smokers, patients with a
diagnosis of periodontitis
Previously diagnosed of type 2
DM with a disease history of
2–5 years, no smokers, HbA1c’s
values less than 7, patients with
a diagnosis of periodontitis
Diagnosis
of generalized, severe, chronic periodontitis, no smokers,
≥20 teeth and bone loss >50% in all teeth, absence of
important systemic diseases, absence of any ongoing
drug therapy, relatively stable glycemic control, HbA1c
levels in the non-diabetic range (<6.1%) in the assay
used for
this study, fasting plasma glucose <6.0 mmol/l
EXCLUSION
CRITERIA
Patients with a DM history of
less than 5 years, with any other
systemic diseases, or who were
under additional medication
Patients with a DM history of
less than 5 years, with any other
systemic diseases, or who were
under additional medication
Females, patients with any
other systemic diseases, insulin
replacement
None of the participants had taken antibiotics,
corticosteroids, or non-steroidal anti-inflammatory
drugs within the 6 months prior to treatment or
undergone periodontal treatment during the previous
2 years, and no individuals included in this study
suffered from hemoglobinopathies capable of altering
the values of HbA1c
DESIGN Observational Case-ControlStudy
Observational Case-Control
Study
Observational Case-Control
Study Observational Case-Control Study
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Table 1. Cont.
STUDY Fusun Unlu (2003) Pelin Guneri (2004) Elif Eser Sakallioglu (2007) Simone Domenico Aspriello (2009)
INDIPENDENT
VARIABLES HgA1c, PD, AL HgA1c, PI, PD, AL PI, GI, PD, GR, AL PI, GI, PD, AL
DEPENDENT
VARIABLES VEGF levels VEGF levels VEGF levels VEGF levels
ANALYSIS METHOD Immunohistochemical analyses Immunohistochemical analyses
Enzyme-linked immunosorbent
assay (ELISA), Biochemical
analysis
Immunohistochemical analysis
STATISTICAL
SIGNIFICANCE
In the negative control group
tissue samples, no VEGF
expression was observed.
Among the 10 systemically
healthy people, no evidence of
VEGF was observed in healthy
gingival samples but was found
in diseased tissues in 2 cases.
In the diabetic patients, VEGF
was observed in 4 healthy
gingival tissues and in 6
periodontal sites. (p = 0.043)
No VEGF staining was
observed in the negative control
group or in the systemically
healthy people’s healthy tissue
samples, whereas four samples
of diabetic patients showed
positive staining (p < 0.05).
However, VEGF was revealed
in two tissue samples of
periodontal sites of systemically
healthy people and in six
samples of the diabetic patients
(p > 0.05). In all test groups,
GCF VEGF levels were higher
in periodontal sites (p < 0.05)
than in healthy sites.
The VEGF concentrations of
gingival supernatants in the test
group were higher than in the
control group. The mean
gingival VEGF level was 55.89 ±
8.11 pg/mL in the test and was
24.81 ± 2.04 pg/mL in the
control group, and the
difference between the groups
was statistically significant (p <
0.01). The mean VEGF level of
GCF in the test group was 38.96
± 4.89 pg/mL, and the mean
VEGF level of GCF in the
control group was 32.20 ± 4.02
pg/mL. The difference in the
VEGF levels of GCF was not
statistically significant between
the groups (p > 0.05)
The three groups
showed no significant differences in the prevalence of
gender and sites of gingival biopsies. Moreover, no
significant
differences in clinical and periodontal parameters
were found among the groups.
Immunohistochemical VEGF expression was observed
in all gingival samples at the cellular cytoplasmic level.
In controls, immunohistochemical analysis showed
diffuse VEGF-positive epithelial cells (39.32–12.72)
mainly in the basal layer. In the dermis, a modest
percentage of VEGF-positive cells (19.86–2.23) was
found; in particular, VEGF-positive endothelial cells
were numerous (38.82–6.73). VEGF-positive cells were
significantly increased in the epithelium of patients with
T1DM (68.55–22.54) and T2DM (55.36–19.99) compared
to controls (p < 0.05), whereas no significant
differences were
found among the three groups for VEGF
expression in dermal cells. A significant increase of
VEGF-positive endothelial cells (49.18–10.17) was
observed in patients with T1DM compared to patients
with T2DM and controls (p < 0.05).
CD34 immunostaining was observed in all gingival
samples. The mean percentage of MVD was 27.40–11.28
in patients with T1DM and was statistically
increased compared to controls (19.57–3.55;
p < 0.05) and patients with T2DM (12.42–6.39; p < 0.001).
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Table 2. Data extraction table.
STUDY Gonca Cayir Keles (2010) Ramya, Senthil Kumar (2014) K. Kranti (2015) Guendalina Lucarini (2016)
PURPOSE
Determine vascular endothelial growth factor
(VEGF) mRNA expression levels in gingival
tissues of gingivitis and periodontitis patients with
diabetes mellitus and those without
Determine the association
between VEGF expression in
healthy and periodontally
diseased tissues of healthy and
diabetic patients
Evaluate
immunohistochemically
vascular endothelial growth
factor (VEGF) and Ki-67 in
human gingival samples and to
compare these factors between
healthy and diabetic patients
Investigate the relation between
vascular endothelial growth
factor (VEGF) and inducible
nitric oxide synthase (iNOS) in
periodontal disease of diabetic
and nondiabetic individuals
SETTING
Department of Periodontology, Faculty of
Dentistry, Ondokuzmayis University,
Samsun, TURKEY
Division of Periodontics, Rajah
Muthiah Dental College &
Hospital, Annamalai University
Department of Periodontics, M
S Ramaiah Dental College and
Hospital, Bangalore, Karnataka
Dental Clinic of the Department
of Clinical Special and Dental
Science (Polytechnic University
of Marche, Ancona, Italy)
SUBJECTS Forty-five subjects, 30–66 years of age n = 3440 to 56 years
n = 50
18 to 65 years
n = 64
47 to 71 years
INCLUSION CRITERIA
Criteria for gingivitis were (1) gingival index
(GI) C2,
(2) probing pocket depth (PPD) 4 mm with
bleeding on
probing, (3) clinical findings such as red color,
swelling of the gingival margin without bone
resorption or periodontal pocketing, (4) no
proximal sites with clinical attachment loss, (5) no
signs of attachment and bone loss observed by
clinical and radiographic examination. Criteria for
periodontitis were (1) GI C2, (2) PPD C4 mm with
bleeding on probing, (3) clinical and radiographic
attachment and bone loss. Criteria for
type II diabetes
were (1) a history of the disease of at least 5 years,
(2) mean hemoglobin A1c value of\7, (3) no insulin
therapy, (4) absence of any other systemic diseases.
Healthy controls without any systemic diseases
showed clinically healthy gingiva without
bleeding (depth of gingival sulcus \3 mm) and no
evidence of periodontal pocketing, clinical
attachment loss or bone resorption
Patients all diagnosed as
chronic periodontitis, based on
the probing pocket depth,
clinical attachment loss (CAL),
plaque index, type II diabetic
and nondiabetic patients with
age group between 40 to 56
years, with mean HbA1c value
ranging between 6 to 8 and
duration not less than five years
Periodontally healthy patients
with no sites with pocket depth
and clinical attachment levels
>3 mm and <20% of sites with
gingival bleeding and bleeding
on probing; patients with
periodontally diseased gingiva
without any systemic disease
and patients with periodontally
diseased gingiva with
controlled type II DM
Inclusion criteria were (1) age
≥18 years, (2) absence of
smoking habit, (3) absence of
major diseases, (4) no history of
allergies, and (5) no use of
antibiotics, corticosteroids, or
non-steroidal anti-inflammatory
drugs within the 6 months prior
to inclusion in the study or
periodontal treatment during
the previous 2 years
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Table 2. Cont.
STUDY Gonca Cayir Keles (2010) Ramya, Senthil Kumar (2014) K. Kranti (2015) Guendalina Lucarini (2016)
EXCLUSION CRITERIA
Systemic diseases (i.e., hypertension,
hyperlipidemia or coronary heart disease), chronic
high dose steroid therapy, radiation or immune
suppressive therapy, chronic usage of
anti-inflammatory drugs, pregnancy, lactation,
smoking or periodontal treatment in the previous
6 months
Smokers, history of any
systemic diseases and
medications influencing the
study
Subjects who were pregnant
and lactating,
on antibiotic therapy, smokers,
on long term administration of
anti-inflammatory medication,
on localized radiation therapy
of the oral cavity and on
antineoplastic chemotherapy
No individuals included in this
study suffered from
hemoglobinopathies capable of
altering the HbA1c values
STUDY DESIGN Observational Case-Control Study Randomized clinical trial Observational Case-ControlStudy
Observational Case-Control
Study
INDIPENDENT VARIABLES GI, PD, HbA1c PI, GI PD, CAL PI, GI, PD, CAL, HbA1c HbA1c, PI, GI, PD, CAL
DEPENDENT VARIABLES VEGF mRNA levels VEGF levels VEGF levels, Ki-67 levels VEGF levels, i NOS levels
ANALYSIS METHOD Real-time RT-PCR Immunohistochemical Analysis Immunohistochemical Analysis Immunohistochemical Analysis
STATISTICAL
SIGNIFICANCE
There was no significant difference in age and
gender distribution between the groups (p > 0.05).
The PPD, CAL, GI, and PI values were not
statistically different between groups 1 and 3 nor
between groups 2 and 4 (p > 0.05). The findings of
GI and PI were not statistically different
between groups
1, 2, 3, and 4. Expression of VEGF mRNA was
detected in all study groups. There was no
significant difference in the expression levels of
VEGF mRNA between the groups
(p > 0.05)
This study showed the
expression of VEGF was found
to be higher in the diseased sites
of diabetic patients with chronic
periodontitis when compared to
their healthy sites. which was
found to be statistically
significant with p-value > 0.001
as assessed by the degree of
staining of monocytes and
endothelial cells
immunohistochemically. There
was a high degree of positive
staining of monocytes with an
increase in the mean number of
cells (50–60%) when compared
to endothelial cells (22–33%)
and was found to be
statistically significant with
p-value > 0.001
The present study found
moderate intensity staining for
VEGF in periodontitis group
and periodontitis with
controlled type II DM group
and mild intensity staining for
VEGF in periodontally healthy
group. With regard to Ki-67,
negative staining was observed
in periodontally healthy group
and mild staining in
periodontitis group and
periodontitis with controlled
type II DM group
No significant difference among
the four groups was found in
age. As expected, glycemia and
HbA1c were significantly higher
in diabetic patients than in
non-diabetic ones. No
difference between DM and
DM+CP group was found in
these two parameters. PI was
statistically significantly higher
in DM+CP group than in the
other groups, whereas GI was
higher in both periodontitis
groups than in the other two.
PD, CAL, and bone loss were
similar in CP and DM+CP
groups, and, as expected, higher
than non-periodontitis groups
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3. Results
The electronic search yielded a total of 26 articles. After examining the full text of articles, 18 of
them were excluded from the review, as showed in Figure 1.
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Figure 1. Flow diagram of information through the different phases of a systematic review.
Of the eight remaini g articles, six reported the results of immunochemist y quantification, one of
ELISA analysis, and one real-time RT-PCR which aimed to quantify mRNA VEGF expression. A total
of 330 patients were enrolled in the studies, and 424 gingival samples were analyzed. Furthermore,
two studies also analyzed the VEGF expression into gingival crevicular fluid. The risk of bias for each
study has been reported (Table 3).
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Table 3. Evaluation of bias risk.
Evaluation of Bias Risk
Patient Selection Test Reference Standard Flow and Timing
Fusun Unlu (2003) Not clear High High Low
Pelin Guneri (2004) Low Low Low Low
Elif Eser Sakallioglu (2007) High Low Low Low
Simone Domenico Aspriello (2009) Not clear High Low Low
Gonca Cayir Keles (2010) Low Low Low Low
Ramya, Senthil Kumar (2014) High High Low Low
K. Kranti (2015) Low High High Low
Guendalina Lucarini (2016) Low High Low Low
Low 4 5 6 8
High 2 3 2 0
Not clear 2 0 0 0
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selected. As a control for specificity of detection, 16 gingival samples from healthy subjects without 
periodontitis were included in the study. The detection of expression of VEGF was conducted in 
epithelial cells and connective tissue cells and in endothelial cells of sub-epithelial connective tissue 
In the study conducted by Lucarini et al. [65], 16 gingival sa ples corresponding to non-diabetic
patients ith periodontitis and 32 gingival sa ples fro diabetic patients ith periodontitis ere
selected. As a control for specificity of detection, 16 gingival sa ples fro healthy subjects ithout
periodontitis ere included in the study. The detection of expression of VEGF was conducted
in epithelial cells and connective tissue cells and in endothelial cells of sub-epithelial connective
tissue vessels by immunohistochemical labeling using specific monoclonal antibodies. Their analysis
demonstrated that epithelial and endothelial cells of the diabetic patients’ group and periodontal
group without diabetes showed strong VEGF immunostaining. Otherwise, endothelial cells and
cells derived from the gingival epithelium of healthy subjects showed moderate immunostaining.
The study of Aspriello et al. [66] described VEGF cytoplasmic expression by immunohistochemical
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staining (IHC) in endothelial cells of gingival tissue samples of 66 patients with periodontitis, including
22 patients with type II diabetes mellitus (T2DM), 22 patients with type I diabetes mellitus (T1DM),
and 22 systemically healthy subjects. Cryostat sections of gingival tissue were immunostained with the
monoclonal antibodies anti-VEGF. For the immunohistochemical study, the semiquantitative was used.
The immunohistochemical data revealed a significant difference in the periodontal expression of VEGF
among the study patients. There was significantly more immunoreactivity to VEGF in the epithelium
of T1DM and T2DM than in the control group (p <0.05). Endothelial cells of patients with T1DM
showed a greater mean (±SD) degree of immunostaining than those of patients with T2DM and patients
without diabetes (p <0.05). Kranti et al. [67] conducted a similar analysis, assessing the expression of
cytoplasmic VEGF in macrophages and fibroblasts. Fifty subjects were analyzed for VEGF expression
by immunohistochemistry. Expression of both line cells VEGF was more moderate in healthy subjects
with periodontitis and patients with controlled type II diabetes mellitus and periodontitis than in the
periodontally healthy group (p <0.01). The discrepancies with the previous study are likely due to the
fact that analysis of VEGF was taken after periodontal treatment, leading to a decrease in inflammatory
response. In contrast, the one study that aimed to analyze the VEGF mRNA expression in gingival
samples, using real-time RT-PCR, failed to detect this overexpression in diseased periodontal tissues
of diabetic patients (Keles et al.) [68]. Specifically, a higher significantly positive amplification of the
mRNA encoding VEGF was observed in healthy subjects than in periodontal groups with or without
diabetes, while the amount of VEGF mRNA did not differ between the diseased groups, and no
statistically significant difference was observed between the groups (p >0.05). This different response
may be attributable to physiological angiogenesis in the periodontium vasculature. Ramya and
colleagues [69] published the results of their research, showing that diseased periodontal sites in the
diabetic patients were correlated with significantly higher levels of VEGF expression when compared
to healthy sites, in accordance with the previous studies (p >0.001). The authors concluded that their
findings may be due to insulin resistance, which appears to stimulate the induction of VEGF expression.
On the other hand, Ünlü et al. [70] detected VEGF subcellular localization using immunochemistry
methods. They reported that positive staining was significantly localized to cytoplasm of monocytes
and macrophages in healthy tissue samples and periodontal sites of diabetic patients, compared
to healthy subjects. Similarly, an increased VEGF expression in diabetic patients was observed by
Sakallioglu et al. [71]. In their study, gingival tissues and GCF samples were drawn from analyzed
sixteen type II diabetes mellitus patients under a good metabolic control condition (HbA1c value less
than seven), and 15 patients under systemically healthy conditions, all with periodontitis. VEGF protein
expression was analyzed by enzyme-linked immunosorbent assay (ELISA). Of interest, compared with
the control group, a slightly higher VEGF concentration of GCF was observed in diabetic patients with
periodontitis, and the difference was not statistically significant (p >0.05). The latter findings indicated
an even stronger gingival tissue response to the diabetic condition when compared to the nondiabetic
patients, showing a higher VEGF concentration, and showing that the intensity of this pro-angiogenic
agent expression in periodontal tissues may be correlated with diabetes. These results were not in
agreement with the previous study conducted by Güneri et al. [72] suggesting that VEGF expression in
periodontal tissues is primarily dependent on the periodontal status and that diabetes might have an
additive effect. The differences among the studies may be due to the characteristics of gingival tissue
samples derived from different degrees of severity of periodontitis in the diabetic group, conditioning
the VEGF expression. A comparison analysis between the studies was not possible because, although
achieved staining by the immunohistochemistry technique was analogous to the results acquired with
the ELISA test (enzyme-linked immunosorbent assay), the interpretation of immunohistochemistry
expression is defined in a subjective manner, and the majority of authors have revealed the VEGF
expression with subjective scoring, while the application of the ELISA test is established as an objective
quantitative method.
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4. Discussion
Angiogenesis is a multi-sequential process characterized by the interaction of a wide variety
of regulatory mediators, in which vascular endothelial growth factor (VEGF) is a protein primarily
involved. The processes underlying the pathogenesis of the microvascular and macrovascular
complications of diabetes have been primarily ascribed to angiogenic factors. Vascular endothelial
growth factors expression is induced by hyperglycemia, advanced glycation end products, and oxidative
stress [72]. This response may result in pathologic neovascularization and altered vascular permeability,
leading to detrimental effects in microvascular tissues, such as the retina. In addition, VEGF is involved
in the pathogenesis of diabetic renal disease, resulting in increased expression in the epithelial cells of
the glomerulus [73], podocyte [74], and collecting ducts. In addition, the clinical observations relating
to diabetic cardiovascular disease have demonstrated a significant pathologic role of VEGF, showing a
much greater expression in human arteriole smooth muscle cells and infiltrating macrophages after
myocardial infarction (MI). Periodontal vasculature, during development of disease, is subjected to the
microvasculature alterations which lead to supporting tissue destruction. There is increasing evidence
that microvasculature of the periodontium is severely affected in diabetic patients with periodontitis,
showing a higher vascular endothelial growth factor (VEGF) expression when compared to healthy
subjects, with or without periodontitis. More recently, evidence has accumulated supporting the
concept that microangiopathy induced by diabetes substantially contributes to periodontal vasculature
alteration in periodontal tissues, inducing the VEGF expression through its capability to induce
microvasculopathy in many organs. However, these results are in contrast with previous studies
reporting that VEGF levels expression was increased in periodontal sites of systemically healthy patients,
compared to patients without periodontitis [55]. Our review showed limited information. Limitations
that may be encountered with this review include discrepancies associated with different VEGF
expression quantification methods (Table 3). The interpretation of immunohistochemistry expression is
generally made in a qualitative and subjective manner, whereas quantification is considered of little or
no importance. A majority of studies used the qualitative (positive or negative) or semiquantitative (0,
1, 2, 3) interpretation of immunostaining, a key limitation of HIC staining. The analysis using staining
scales is subject to interobserver variability and is often based on cellular presence or absence of a
specific molecule. In addition, the evaluation of immunostaining may be influenced by heterogeneity
of biologic VEGF expression between tissue samples and gingival crevicular fluid, which is susceptible
to the saliva concentration fluctuation. In the majority of studies, a positive result referred essentially
to the presence of brown staining (peroxidase), leading to confounding factors [41–43]. Similarly,
two authors assessed VEGF expression analysis in which the results of the immunohistochemical
investigation revealed marked cytoplasmic staining, but this analysis is considered to be non-specific.
Additionally, difficulty in the interpretation and comparison of immunohistochemical studies included
variability in patient selection, different immunohistochemical criteria used for determining the staining
degree, and bias associated with the statistical method of analysis data. For instance, studies applying
immunochemistry analysis revealed a globally increased VEGF expression in periodontal sites in
diabetic patients compared to healthy subjects. Interestingly, although the reduced VEGF expression
level in patients after periodontal treatment was obvious, this result might be of relevance, because
improvement of inflammatory status has been shown to reduce the angiogenesis [45,54]. However,
although from these results we can assume that the periodontal vasculature is affected by diabetes,
and the VEGF expression may influence periodontal disease progression, further investigation
establishing the degree of disorder at different disease stages of diabetic patients with periodontal
disease are needed [63], because the duration and degree of hyperglycemia in diabetes may also be
critical, as well as the periodontal status. Nonetheless, as suggested by this, we cannot exclude the
involvement of preexisting periodontal inflammation, as the author hypothesized that preexisting
periodontal disease in patients with diabetes might partly explain increased VEGF expression and
impact on outcome.
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5. Conclusions
The current paradigm of linkage between type 2 diabetes and periodontitis must be integrated.
We recognize an additional factor impacting the risk of periodontitis in patients with diabetes that
may inform this discussion of new paradigms. This review has highlighted the detrimental effect
of diabetes on periodontal tissues, resulting also from the induction of overexpression of VEGF,
responsible for pathological angiogenesis. To date, an extremely limited number of studies have
addressed the overexpression of VEGF in the periodontium of diabetic patients, and partially conflicting
results have been reported. Expression of VEGF in diabetic patients with periodontitis has been
demonstrated [21], but no conclusive data on inductive effect of periodontal damage have been
published. However, the pivotal role of diabetes, and its signaling system in periodontal tissues,
remains largely unexplored. Although expression of VEGF in the periodontium has been preliminarily
reported, further investigations are needed for an appropriate conclusion in this linkage. In addition,
clinical trials exploring new treatment strategies that target both diseases are required.
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